Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer

Genome Medicine

Volumn 1, Issue 4, 2009, Pages

  Boardman, Lisa A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METASTASIS ASSOCIATED IN COLON CANCER 1; ONCOPROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; DISEASE MARKER; GENE ACTIVATION; GENE CONTROL; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 70350339827     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm36     Document Type: Short Survey

References (29)

1. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O: Tumour markers in colorectal cancer: European group on tumour markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43:1348-1360.
2. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009, 15:59-67.
3. Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, Fonatsch C, Tsubouchi H, Hishida T, Daikuhara Y, Birchmeier W: Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Nat Acad Sci USA 199, 88:7001-7005.
4. Neklason DW, Kerber RA, Nilson DB, Anton-Culver H, Schwartz AG, Griffin CA, Lowery JT, Schildkraut JM, Evans JP, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Finkelstein DM, Nadkarni PM, Kasten CH, Mineau GP, Burt RW: Common familial colorectal cancer linked to chromosome 7q31. Cancer Res 2008, 68:8993-8997.
5. Watanabe M, Ueno Y, Yajima T, Iwao Y, Tsuchiya M, Ishikawa H, Aiso S, Hibi T, Ishii H: Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest 1995, 95:2945-2953.
6. Carrolo M, Giordano S, Cabrita-Santos L, Corso S, Vigario AM, Silva S, Leiriao P, Carapau D, Armas-Portela R, Comoglio PM, Rodriguez A, Mota MM: Hepatocyte growth factor and its receptor are required for malaria infection. Nat Med 2003, 9:1363-1369.
7. Choi DS, Kim HJ, Yoon JH, Yoo SC, Jo H, Lee SY, Min CK, Ryu HS: Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor. Int J Cancer 2008 [Epub ahead of print].
8. Ma J, Defrances MC, Zou C, Johnson C, Ferrell R, Zarnegar R: Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest 2009, 2 Feb pii:36640.
9. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR: Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007, 248:219-228.
10. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang HJ, Hoon DS: c-met expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003, 9:1480-1488.
11. Umeki K, Shiota G, Kawasaki H: Clinical significance of c-met oncogene alterations in human colorectal cancer. Oncology 1999, 56:314-321.
12. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004, 10:3069-3075.
13. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Van de Woude GF: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311:29-33.
14. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn C, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinoma. Nat Genet 1997, 16:68-73.
15. Park WS, Dong SM, Kim SY, NA EY, Shin MS, Pi J, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999, 59:307-310.
16. Bardelli A, Comoglio PM: Scatter factor receptors are key players in a unique multistep program leading to invasive growth. In Plasminogen-related Growth Factors. Volume 212. Ciba Foundation Symposium. Chichester: Wiley; 1997:133-147.
17. Baldus SE, Kort EJ, Schirmacher P, Dienes HP, Resau JH: Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and non-neoplastic epithelia by quantitative laser scanning microscopy. Int J Oncol 2007, 31:199-204.
18. Toschi L, Jänne PA: Single-agent and combination therapeutic strategies to inhibit Hepatocyte Growth Factor/MET signaling in cancer. Clin Cancer Res 2008, 14:5941-5946.
19. Furge KA, Zhang YW, Vande Woude GF: Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000, 19:5582-5589.
20. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM: The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002, 4:720-724.
21. Matsumoto K, Nakamura T: NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci 2008, 13:1943-1951.
22. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006, 66:1721-1729.
23. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K: A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006, 12:6144-6152.
24. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M: MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008, 68:4360-4368.
25. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y: The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004, 23:5387-5393.
26. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD, Comb MJ: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008, 105:692-697.
27. Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC: The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 2008, 14:3814-3822.
28. Camp RL, Rimm EB, Rimm DL: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86:2259-2265.
29. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL: Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998, 82:1513-1520.